Original Article

Percutaneous Mitral Balloon Valvotomy. Long-term Outcome and Assessment of Risk Factors for Death and Major Events

Ivana Picone Borges, Edison Carvalho Sandoval Peixoto, Rodrigo Trajano Sandoval Peixoto, Paulo Sergio de Oliveira, Mario Salles Netto, Pierre Labrunie, Marta Labrunie, Ricardo Trajano Sandoval Peixoto, Ronaldo de Amorim Villela
Rio de Janeiro, RJ / Niterói, RJ - Brazil

Objective
To identify the factors that predict death and combined events, (death, new mitral balloon valvotomy, or mitral valve surgery) in long-term follow-up of patients undergoing percutaneous mitral balloon valvotomy.

Methods
Follow-up was 49.0±31.0 (1 to 122) months. Techniques used were the single-balloon (84.4%), Inoue-balloon (13.8%), and double-balloon techniques (1.7%).

Results
Included in the study were 289 patients 38.0±12.6 years of age (range, 13 to 83). Before the procedure, 244 patients had echocardiographic score \( \leq 8 \), and 45 patients had score >8. Females comprised 85%, and 84% patients were in sinus rhythm. During follow-up, survival of the total group was 95.5%, that of the group with \( \leq 8 \) was 98.0%, finally that of the group with scores >8 was 82.2% (P<0.0001), whereas combined event-free survival was 83.4%, 86.1%, and 68.9%, respectively (P<0.0001). In the multivariate analysis, the factors that predicted long-term death were a preprocedure echocardiographic score >8 and the presence of severe valvular mitral regurgitation during the procedure. The events that predicted combined events were a previous history of mitral valvular commissurotomy and atrial fibrillation and the presence of severe mitral valvular regurgitation during the procedure, and postprocedure mitral valvular area <1.5 m\(^2\) (failure).

Conclusion
Percutaneous mitral balloon valvotomy is an effective procedure, and over 2/3 of the patients were event-free at the end of follow-up. Survival in the group was high, even higher in the group with lower echocardiographic scores.

Key words
mitral valvular stenosis, mitral stenosis, mitral balloon valvotomy, rheumatic fever
between 24 and 28 mm. If a new mitral regurgitation occurred or the level of previous mitral regurgitation worsened during the procedure, regurgitation was quantified using Sellers et al’s classification. The mean gradient before and after the procedure was measured in 2 ways: 1st) by the 3-point method and 2nd) by planimetry of the gradient area. The mitral valvular area before and after dilation was determined, assessing the cardiac output by thermal dilution and using Gorlin and Gorlin’s formula. The follow-up was performed by telephone or letter. The following were assessed: functional class (FC) according to NYHA, mortality and the cause of death, medication used, performance of mitral valve surgery or of new balloon mitral valvotomy. After the questionnaire was filled in, 1-dimensional and 2-dimensional Doppler echocardiogram was performed in 224 cases. Clinical evolution of patients in the study was considered as of the first month after the procedure. Mitral valve area was assessed using planimetry or transmitral pressure half-time. Mitral valvular morphology was assessed using Wilkins’ score. The level of mitral regurgitation was assessed by Doppler echocardiography according to the extension of the regurgitant flow in the left atrium, classified as mild, moderate, and severe. All patients underwent echocardiography before undergoing mitral valve valvuloplasty. At the beginning and end of the procedure, mitral valvular area was assessed by hemodynamic calculation and the level of regurgitation by left ventriculography.

Patients were also divided into 2 subgroups A and B, using Wilkins’ score. Group A with scores ≤8 and group B with scores > 8.

Success was defined as mitral valvular area ≥1.50 cm², obtained after the procedure by using hemodynamic assessment without severe mitral failure. Failure was defined as mitral valvular area <1.5 cm².

Severe mitral regurgitation grade 3 or 4+ was determined by using Sellers’ classification.

Comparison between continuous variables was performed using the Student t test, when the distribution was normal; otherwise, the Mann-Whitney test was used. Comparison between categorical variables was performed using the chi-square test, the chi-square test with Yates comparison, and Fisher’s exact test, according to the frequency of events, using EPI INFO’s software program for the calculation and as a databank. A multivariate model of Cox’s proportional risks was built to identify the independent factors predicting death and major events combined with death, new balloon mitral valvotomy, and mitral valvular surgery in a long-term follow-up, using SPSS 8 software program. Survival and event-free survival curves were created using the Kaplan-Meier method, and compared, using Log Rank, Breslow, and Tarone-Ware’s models. Multivariate analysis on steps was used to identify the independent factors predicting death and combined events in the long-term outcome. Relative risk of the variables related to time was assessed and the confidence Cox’s regression model underwent multivariate analysis. Variables selected for multivariate analysis were age, success, presence of severe mitral regurgitation after procedure, effective balloon dilation area, the diameter of the dilation balloon of the mitral valve, cardiac rhythm, history of surgical mitral commissurotomy, score ≤8 and > 8, and score ≤11 and < 11.

Results

Follow-up was completed of 289 patients. All of them had a completed procedure and at least 1 month of follow-up, 49.0±31.0 (1 to 122) months; 246 (85.1%) patients were females, with ages 38.0±12.6 (13 to 83) years old. Four patients were in NYHA FC I (1.4%), 72 patients (24.9%) were in FC II, 184 patients (63.7%) were in FC III, and 29 patients (10.0%) were in FC IV. Forty-five patients (15.6%) had atrial fibrillation, and 244 (84.4%) had sinus rhythm. Twenty-five patients (8.7%) had a history of previous surgical commissurotomy, and 9 patients (3.1%) had mitral balloon valvotomy. The echocardiographic score ranged from 4 to 14 (7.3±1.5), 244 patients (84.4%) had echocardiographic score ≤8, group A, and 45 (15.6%) > 8, group B. Echocardiographic mitral area, before mitral valvotomy, was 0.90±0.21 cm²; in group A it was 0.93±0.21 cm², and in group B it was 0.91±0.20 cm² (p=0.5627). Of all the procedures, 244 (84.4%) were performed with the single-balloon, 40 (13.8%) with the Inoue, and 5 (1.7%) of 29.5±1.2 mm and a maximum dilation area 6.87±0.49 cm². Mean pulmonary artery pressure, mean mitral valvular gradient and mitral valvular area before and after balloon valvotomy were 38.0±14.3 and 26.7±10.1 mmHg (p<0.0001), 19.2±7.0 and 5.4±3.5 mmHg (p<0.0001), and 0.90±0.21 and 2.00±0.39 cm² (p=0.0139), respectively. Of all the procedures, 261 were successful (90.4%) and 19 (6.6%) were unsuccessful; mitral valvular area after mitral balloon valvotomy was not assessed in 9 procedures (3.1%). Before mitral valvotomy, grade 1+ mitral regurgitation was present in 44 patients (15.2%), grade 2+ in 1 patient (0.3%), and the valve was competent in 244 patients (84.4%). After mitral valvotomy, the valve was competent in 207 (71.6%) patients, and grade 1+ mitral regurgitation occurred in 61 patients (21.1%), grade 2+ in 18 patients (6.2%), grade 3+ in 2 patients (0.7%), and grade 4+ in 1 patient (0.3%). Severe complications occurred in 5 patients of the 289 patients, 3 patients (1.0%) had severe mitral regurgitation, and 2 patients had cardiac tamponade, drained in the hemodynamic room. All patients remained with clinical evolution for at least 1 month without a surgical procedure for mitral valve replacement.

In the final follow-up lasting 49.0±31.0 (1 to 122) months, NYHA FC was I in 141 (48.8%) patients, FC II in 82 patients (28.4%), FC III in 49 patients (17.0%), and FC IV in 4 patients (1.4%), with 13 (4.5%) deaths. Group A, with 244 patients, had, according to the NYHA, 124 patients in FC I, 69 in FC II, 43 in FC III, 3 in FC IV with 5 deaths, and group B, with 45 patients, had 17 in FC I, 13 in FC II, 6 FC III, 1 in FC IV with 8 deaths (p=0.0001). Echocardiography was performed at the end of follow-up in 244 patients with mitral area 1.56±0.49 cm²; 97 (44.1%) of the 244 patients had valvular area ≤1.50 cm²; in group A it was 1.58±0.50 cm², and in group B it was 1.42±0.39 cm² (p=0.1042). Preprocedure mean mitral valvular area assessed through echocardiography was 0.93±0.21 cm² and 0.91±0.20 cm² (p=0.5627) in groups A and B, respectively (tab. I). Mean mitral valve area, assessed through the hemodynamic method, was 0.90±0.22 and 0.94±0.21 (p=0.2075), respectively, in groups A and B (tab. I). Mitral valvular area (Gorlin), immediately after balloon mitral valvotomy was higher in group A 2.03±0.39 cm² compared with that in group B 1.83±0.37 cm² (p=0.0016). In the 224 patients undergoing...
echocardiography during follow-up, the mitral valve was competent in 60 patients (26.8%), and grade 1+ mitral regurgitation was present in 118 patients (52.7%), grade 2+ in 24 patients (10.7%), grade 3+ in 12 patients (5.4%), and grade 4+ in 10 patients (4.5%). Three patients with severe mitral regurgitation started follow-up, and all of them died, one during the surgical procedure. During follow-up, 19 new cases of severe mitral regurgitation occurred, 9 patients underwent surgery with one death, and 10 had clinical evolution or waited for surgery. Fourteen patients (4.8%) underwent new mitral balloon valvotomy; 7 patients (9.3%) underwent mitral valve surgery, 16 due to mitral stenosis, 6 due to severe mitral regurgitation; and 5 due to double mitral lesion. During follow-up, 13 deaths (4.5%) occurred, 11 (3.8%) due to heart problems, 1 (0.7%) due to stroke, and 1 (0.7%) had no reported cause. Of the cardiac deaths, 6 occurred during mitral valve replacement, 4 due to acute pulmonary edema, and 1 due to heart failure. Late mortality was greater in group B, with 8 deaths (17.8%) in 45 patients, versus 5 deaths (3.5%) in 244 patients in group A (p=0.0001) (tab. I). In the total group, 48 (16.6%) combined events occurred. At the end of follow-up, however, number of combined events was lower in group A, 34 events (13.9%) compared with those in group B, 14 events (31.1%), p=0.0010 (tab. I). Survival of the total group at the middle compared to countries such as India43 (26 years old, was the mean age in the study of Kaul et al43), Tunis16,17, and Egypt44 (29 years old, was the mean age in the study of Kaul et al43), with younger patients, and the mean ages of countries in Europe40,43,45, United States44,46, and Japan38,47, with much older patients. In the American studies of Palacios et al24, Cohen et al48, and Pathan et al49 mean age of patients studied was 55, 59, and 58 years old, respectively. Two Japanese studies38,47 presented mean ages of patients 51 and 52 years old.

Women were predominantly, corresponding to 85.1% of the patients in this study, which is in accordance with the literature16,17,24,36,38,40.

Previously to balloon mitral valvotomy, most patients were in NYHA FC III (63.7%), and IV (10%), 73.7% total, also in accordance with the literature17,24,37,49. Currently, patients in NYHA FC II and, exceptionally, those in FC I are accepted to undergo balloon mitral valvotomy17,49. In the end of follow-up, 77.2% of patients were in FC I and II, 26.6% were not given any medication, and 18.4% of patients were in FC III, and IV. Farhat et al16 observed that 95% of patients were in FC I and II after 37±22 months of follow-up and. After a 7 year-follow-up of a selected population with favorable characteristics, 93.6% of the population was in

### Table I - Valve area, mortality and events in the groups with echocardiographic score ≤ 8 and > 8

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events in the follow-up (n.%)</td>
<td>34 (13.9)</td>
<td>14 (31.1)</td>
<td>0.0010</td>
</tr>
<tr>
<td>Mortality in the follow-up (n.%)</td>
<td>5 (3.5)</td>
<td>8 (17.8)</td>
<td>0.0001</td>
</tr>
<tr>
<td>MVA Echo pre-PBMV (cm²)</td>
<td>0.93±0.21</td>
<td>0.91±0.20</td>
<td>0.5627</td>
</tr>
<tr>
<td>MVA Hemo pre-PBMV (cm²)</td>
<td>0.90±0.22</td>
<td>0.94±0.21</td>
<td>0.2075</td>
</tr>
<tr>
<td>MVA Hemo post-PBMV (cm²)</td>
<td>2.03±0.39</td>
<td>1.83±0.37</td>
<td>0.0016</td>
</tr>
<tr>
<td>MVA Echo follow-up (cm²)</td>
<td>1.58±0.50</td>
<td>1.42±0.39</td>
<td>0.1042</td>
</tr>
<tr>
<td>MVA - mitral valve area; Echo - echocardiographic; Hemo - hemodynamic (thermodilution and Gorlin’s formula); Group A - echocardiographic score ≤ 8, Group B - echocardiographic score &gt; 8; PBMV - percutaneous balloon mitral valvotomy.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Discussion

Mitrail balloon valvotomy arose as an alternative to surgical treatment in patients with severe mitral stenosis. It is necessary to know the factors predicting death and major events in order to indicate this procedure as accurately as possible. Population is different in age, clinical and echocardiographic characteristics among the countries in Europe, North America, Asia, Africa, and South America.

Studies with the analysis of the outcome from different periods of follow-up are found in the literature, these studies range from 1 to 12 years of follow-up after the performance of mitral balloon valvotomy17,18,21,24,34,42.

Mean age of our patients was 38.0±12.6 years old, it was in the middle compared to countries such as India43 (26 years old, was the mean age in the study of Kaul et al43), Tunis16,17, and Egypt44 (29 years old, was the mean age in the study of Zaki et al44) with younger patients, and the mean ages of countries in Europe20,37,45, United States34,46, and Japan38,47, with much older patients. In the American studies of Palacios et al24, Cohen et al48, and Pathan et al49 mean age of patients studied was 55, 59, and 58 years old, respectively. Two Japanese studies38,47 presented mean ages of patients 51 and 52 years old.

Factors predicting long-term survival in the univariate analysis were echocardiographic score ≤ 8 (p=0.0001), echocardiographic score ≤ 1 (p<0.0001) age of the patient < 50 years old (p=0.0016), absence of severe mitral regurgitation per procedure (p<0.0001), sinus rhythm (p=0.0034), mitral balloon diameter ≥ 28 mm (p=0.0005), mitral dilation effective area > 6 cm² (p=0.0005) and mitral valve area (Gorlin) ≥ 1.5 cm² (success) (p=0.0065).

Factors predicting combined event free survival in the univariate analysis were: sinus rhythm (p=0.0005); mitral dilation balloon diameter ≥ 28 mm (p=0.0005); effective area of mitral dilation ≥ 6 cm² (p=0.0036) and mitral valve area ≥ 1.5 cm² (p<0.0001), echocardiographic score ≤ 8 (p=0.0017); echocardiographic score ≤ 11 (p<0.0001); absence of previous surgical mitral commissurotomy (p=0.0235), absence of severe mitral regurgitation per procedure (p<0.0001) and age of the patient < 50 years old (p=0.0013).

In the multivariate analysis factors predicting long term survival were: echocardiographic score ≤ 8 (p=0.0003) and absence of severe mitral regurgitation during mitral valvotomy (p=0.0001) and event free survival: absence of severe mitral regurgitation after balloon valvotomy (p=0.0038), absence of previous surgical mitral commissurotomy (p=0.0077), mitral valve area assessed through hemodynamic after the procedure ≥ 1.5 cm² (p=0.0005) and sinus rhythm (p=0.0220), (tab. II).

There was a significant difference in the survival Kaplan-Meier curves (log rank) for: echocardiographic score ≤ 8 and echocardiographic score > 8 (p<0.0001), presence or absence of severe mitral regurgitation during procedure (p<0.0001) and event free survival for: presence or absence of previous commissurotomy (p=0.0191), presence or absence of severe mitral regurgitation per procedure (p<0.0001), sinus rhythm or atrial fibrillation (p=0.0011), (fig. 1) and mitral valve area after the procedure using Gorlin’s method < 1.5 cm² and ≥ 1.5 cm² (p=0.0001), all of them were significant variables in the multivariate analysis. Additionally the patients’ survival and event free survival curves were studied. They were divided into 3 score groups: echocardiographic score ≤ 8, from 9 to 11, and ≥ 12 (fig. 2 and 3), all of them with diverse outcomes and statistical significance.

### Table II - Valve area, mortality and events in the groups with echocardiographic score ≤ 8 and > 8

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events in the follow-up (n.%)</td>
<td>34 (13.9)</td>
<td>14 (31.1)</td>
<td>0.0010</td>
</tr>
<tr>
<td>Mortality in the follow-up (n.%)</td>
<td>5 (3.5)</td>
<td>8 (17.8)</td>
<td>0.0001</td>
</tr>
<tr>
<td>MVA Echo pre-PBMV (cm²)</td>
<td>0.93±0.21</td>
<td>0.91±0.20</td>
<td>0.5627</td>
</tr>
<tr>
<td>MVA Hemo pre-PBMV (cm²)</td>
<td>0.90±0.22</td>
<td>0.94±0.21</td>
<td>0.2075</td>
</tr>
<tr>
<td>MVA Hemo post-PBMV (cm²)</td>
<td>2.03±0.39</td>
<td>1.83±0.37</td>
<td>0.0016</td>
</tr>
<tr>
<td>MVA Echo follow-up (cm²)</td>
<td>1.58±0.50</td>
<td>1.42±0.39</td>
<td>0.1042</td>
</tr>
<tr>
<td>MVA - mitral valve area; Echo - echocardiographic; Hemo - hemodynamic (thermodilution and Gorlin’s formula); Group A - echocardiographic score ≤ 8, Group B - echocardiographic score &gt; 8; PBMV - percutaneous balloon mitral valvotomy.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Percutaneous Mitral Balloon Valvotomy. Long-term Outcome and Assessment of Risk Factors for Death and Major Events

FC I and FC II 17. Iung et al 29 found 56% of patients in FC I and FC II, after a 10-year-follow-up. However, when they studied a population of patients with calcified valve they observed that only 36% of them were in FC I and II, after 8 year of follow up.

Most patients (84%) in this study were in sinus rhythm when mitral valvotomy was indicated. Farhat et al 16 reported 71% of patients in sinus rhythm before the procedure both studies had a young population. Studies with an older population usually have a higher echocardiographic score and higher incidence of atrial fibrillation. Some authors stress that the presence of atrial fibrillation is a factor that would predict events in long-term follow-up 20,22,23,51 which is in accordance with our study (fig. 1), however, other authors do not agree with that premise 24,36,37,49,39,52,53.

In this study and in the literature, mitral balloon valvotomy immediately decreases left atrium pressure and pulmonary vessels, enabling relieve of symptoms immediately 16,18,23,24,48,54-57. There was a decrease in pulmonary pressure in the presence of severe hypertension even in the presence of elevated systemic levels 57.

In the present study, 84.4% of patients presented echocardiographic score ≤8 before the procedure, in accordance with the other in the literature 24,54,58. The group of patients with echocardiographic score ≤8 had more satisfactory immediate results (p=0.0016), just as those in the literature 24,36,54,58. When functional class and long-term death were assessed, the group with lower score presented a more favorable outcome (p=0.0001). These patients were younger, with higher incidence of atrial fibrillation, lower calcification; lower Functional Class, lower level of mitral regurgitation before the procedure, and lower incidence of previous surgical commissurotomy. Despite the less satisfactory results, in the group with echocardiographic score >8, when compared to the group with lower score, our study demonstrated that mitral balloon valvotomy is an alternative to mitral stenosis treatment, with good results, even though they may be inferior to

<table>
<thead>
<tr>
<th>Variable</th>
<th>Survival free of</th>
<th>Significance</th>
<th>Relative Risk</th>
<th>Confidence interval (95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCORE - score ≤8</td>
<td>Death</td>
<td>0.0003</td>
<td>0.1182</td>
<td>0.0372 0.3759</td>
</tr>
<tr>
<td>Severe mitral regurgitation - Absent</td>
<td>Death</td>
<td>0.0001</td>
<td>0.0331</td>
<td>0.0059 0.1869</td>
</tr>
<tr>
<td>Previous commissurotomy Absent</td>
<td>Major Events</td>
<td>0.0077</td>
<td>0.3495</td>
<td>0.1613 0.7572</td>
</tr>
<tr>
<td>Mitral valve area (Gorlin) ≥ 1.5 cm²</td>
<td>Major Events</td>
<td>0.0005</td>
<td>0.2201</td>
<td>0.0943 0.5137</td>
</tr>
<tr>
<td>Absent severe mitral failure Sinus Rhythm</td>
<td>Major Events</td>
<td>0.0038</td>
<td>0.0783</td>
<td>0.0140 0.4385</td>
</tr>
<tr>
<td>Mitral valve area (Gorlin and Gorlin) - mitral valve area after the procedure by Gorlin’s method (success) &lt;1.5 cm² and ≥ 1.5 cm²; SCORE - echocardiographic score ≤8 and echocardiographic score &gt; 8; major events - death, new balloon mitral valvotomy and mitral valve surgery; severe mitral regurgitation per-procedure grade 3 and 4 + (Sellers et al 25).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1 - Event free survival curve (Kaplan-Meier). Sinus rhythm or atrial fibrillation (Log Rank, p=0.0011; Breslow, p=0.068 and Tarone-Ware, p=0.0023).

Fig. 2 - Survival curve (Kaplan-Meier). Echocardiographic score ≤8, from 9 to 11 and echocardiographic score ≥ 12 (Log Rank, Breslow and Tarone-Ware, p<0.0001).

Fig. 3 - Event free survival curve (Kaplan-Meier). Echocardiographic score ≤8, from 9 to 11 and echocardiographic score ≥ 12 (Log Rank, Breslow and Tarone-Ware, p<0.0001).
the other group, especially when the echocardiographic score is ≤11. Palacios et al. 24 demonstrated statistically significant difference in the success rate of the procedure for the group with score ≤8, related to mortality, need for mitral valve surgery and incidence of FC III and IV greater, in the long term, in the group with echocardiographic score >8. 24. Hilddick-Smith et al. 36, had successful results in 61% of cases, and a 6-year-event-free-survival in 56% of cases in a group of patients with unfavorable characteristics to procedure, including 59% of patients with echocardiographic score >8.

In this study, mitral valve was competent before the procedure in 84.4% of cases, and the rest were divided into grade 1+ or grade 2+ mitral regurgitation according to the classification of Sellers et al. 25. After the procedure, 71.6% of patients remained with competent mitral valve and 1% of patients followed-up for at least one month presented severe mitral regurgitation. This percentage of mitral regurgitation does not reflect our total group, where the incidence of severe mitral regurgitation was 2.5% 42. Palacios et al. 24 obtained 9.4% of severe mitral regurgitation after the procedure higher in the group with echocardiographic score >8. In the study by Hernandez et al. 37 the incidence of this complication was 4%, in the study by Kaul et al. 43 it was 3.3%, in that by Jung et al. 45 it was 4%, and in that by Farhat et al. it was 4.6% 16.

Just as occurred in this study, the authors identified this complication as a factor predicting long term events23,24,37,40,53,59. Zhang et al. 23 compared patients with or without mitral regurgitation before the procedure, and observed that patients with pre-existing mitral regurgitation were older and presented more events in the long term outcome. Hernandez et al. 37 found 4% of severe mitral regurgitation after the procedure unrelated to age or echocardiographic score and cases of mild or moderate mitral regurgitation after the procedure, with likelihood to regress or at least not worsen. Leaflets rupture led to severe mitral regurgitation and need for emergency surgery in all patients 45. There was a decrease in the level of mitral regurgitation over time in 1.6% of patients, and probably the regurgitation mechanism was the consequence of the intensive stretching of mitral commissurotomy 37,43. Severe mitral regurgitation may be predicted, through echocardiographic score specific to it 46. Mitral regurgitation before balloon valvuloplasty is a factor that predicts lower long term event free survival23, in older patients usually presenting mitral calcification and atrial fibrillation, compared to patients without concomitant mitral regurgitation. In our study, only 224 patients underwent echocardiogram in late follow-up and it was observed that 26.8% still presented competent mitral valve and there were 9.9% cases of severe mitral regurgitation. Three patients with severe mitral regurgitation in the post immediate period were maintained in this study for at least 1 month, and 19 new cases of severe mitral regurgitation were identified during our follow-up (7.79%). Kaul et al. 43 found 3.3% cases of severe mitral regurgitation in the post immediate period, 55% needed emergency valve replacement and, in the end of follow-up, they observed 8.4% of cases with severe mitral regurgitation, and 37.66% of cases requiring mitral valve surgery.

In the end of follow-up, through echocardiogram, mean mitral valve area was 1.56±0.49 cm², 1.58±0.50 cm² in the group with echocardiographic score ≤8 and 1.42±0.39 cm² in the group with echocardiographic score >8 (p=0.1042). There was a 0.44 cm² loss of mitral valve area, on average in 49±31 months, in the total group. Mitral valve area immediately after the procedure assessed by hemodynamic (Gorlin27) was on average 2.00±0.39 cm², with statistically significant difference between the 2 groups, higher in the group with echocardiographic score ≤8. Loss of mitral area may be a result of rheumatic disease development, and/or presence of blood flow turbulence in the deformed valves 61. After mitral valvuloplasty, Hernandez et al. 37 found a >0.3 cm² mitral valve area loss in 12%, 22%, and 27% of patients in 3, 5, and 7 years respectively, on average, 0.13±0.21 cm². Loss of valve mitral area in the literature ranged from 0.16 to 0.4 cm² for diverse groups and in different outcome periods 17,38,49,62,63. Loss of mitral valve area, in the study of Wang et al. 46, was 0.06 cm² per year after the performance of balloon valvuloplasty. We could observe in our study, in the end of the follow up period, 97 patients (44.1%) with mitral valve areas smaller than 1.50 cm². This criterion was used in the study to define restenosis, and it was the same adopted by other authors17,51. Mitral restenosis occurred in 44.1% of patients in a mean 49±31 follow-up period in this study, defined as mitral valve area < 1.50 cm². In the literature we have observed different restenosis frequency among the studies, ranging from 36 months to 7 years as well as different population and restenosis criteria. Restenosis definition may be done clinically or in terms of mitral valve area, by absolute loss or percentual loss, or loss of mitral valve gain after balloon valvuloplasty16-18,36,37,46,47,51; the definition of restenosis varies among authors, usually it is referred as loss of 50% or over of the initial gain and/or mitral valve area < 1.5 cm². Wang et al. 46 observed gradual and progressive loss of the mitral valve area, after balloon mitral valvuloplasty and absence of correlation between mitral valve area after the procedure and restenosis, suggesting that it is a part of an ongoing biological process rather than a mechanical or retraction process.

In the present study there were 13 cases (4.5%) of death in the and end of the follow-up period, 11 (3.8%) had cardiac origin, and 46.15% of the cardiac deaths occurred in mitral valve surgery, performed in different hospitals. Farhat et al. 36 found 7 cases (1.6%) in the end of the 37±22 month-period, and another study of the same authors 17, with young patients with favorable characteristics, mortality was null in 7 years. Meneveau et al. 21 found a 6% mortality in 3 years, reaching 17% in 7 years and a half of follow-up. Palacios et al. 24 found 13.03% of death in a follow-up of 4.2±3.7 years, 10.07% had cardiac origin. Hamasaki et al. 38 found a mortality of 2%, 7%, and 14% in 1, 3 and 6 years, respectively. Hernandez et al. 37 found 5% of death in 39±23 months, 3.3% had cardiac origin. Hamsaki et al. 38 found a mortality of 2%, 7%, and 14% in 1, 5 and 10 years, respectively, of follow-up. Wang et al. 46 found 11 deaths (3.58%), only 2 (18%) had cardiac origin. Jung et al. 45 found 0.4% of deaths during outcome. In this study when both echocardiographic score groups were compared, higher mortality was observed in the group with echocardiographic score >8, 17.8% against 3.5% in the group with echocardiographic score ≤8 (p=0.0001). Palacios et al. 24 also found higher mortality in the group with higher echocardiographic score. Thus, reported mortality during outcome is null in groups selected with favorable medium term 64,65, and even long term9 characteristics. Mortality reached 17 and 18% 21,36,
due to the unfavorable characteristics or when greater follow-up period were observed.

In the long-term follow-up, survival varied considerably, from 82% to 100% in 5 to 7 year-follow-up, 17-18,21-34,36,37,38, probably due to clinical and echocardiographic difference of the population studied. In a longer period between 10 to 12 years of follow-up, survival reported was 82% and 86%24,38. Long term results are less satisfactory in Europe and North America24,45,48,54, with older patients and more involved valve anatomy. Survival in this study, in the end of follow-up was 95.5% in the total group of patients, 98% in the echocardiographic score group ≤8, higher than that of the group with echocardiographic score >8, which was 82.8% (p<0.0001).

Event free survival in this study, in the end of follow-up was 83.4% greater in group A (86.1%) when compared to group B (68.9%), (p<0.0001). In the literature, we have found percentages ranging from 16% to 90% with follow-up ranging from 4 to 12 years17,18,24-37,45,47,48,66, due to the difference of the groups of patients. Lung et al 45 found a 58% event free survival in 8 years of follow-up, however those were patients undergoing balloon mitral valvuloplasty because of restenosis after surgical commissurotomy. Farhat et al 17 found a 90% event free survival in 7 years, in a group of young patients, just as did Zaki et al 18, who found 91% in 5 years. Sutaria et al 19 found event free survival of 36% of elders in 5 years, in a 6-year- follow-up, Saeki et al 47 found 88% of event free survival, and Lung et al. 20, in a 10-year-follow-up found 56.4% event free survival. Maneveau et al 21 compared event free survival of the group with favorable mitral valve anatomy, with that of the group with unfavorable, and they found 70% and 16%, respectively, in 7 years of follow up. Lung et al 22, found 36% in 8 years, in patients with calcified valves. Zhang et al 23 found event free survival in a 6-year-period in a group with mitral regurgitation in 37% of patients and in 69% in the group without mitral regurgitation. Palacios et al 24, in a 12-year-follow-up, found a 38% event free survival, in the group with echocardiographic score ≤8, and 22% in the group with increase score. Hernandez et al 37 found 69% event free survival in a 7-year-follow-up, in patients with low score, whereas Cohen et al 48 found 51%, in a 6-year-follow-up, in patients with low echocardiographic score and increased age. Dean et al 66, in the Record of NHLBI, found a 60% event free survival in a 4-year-follow-up.

Through multivariate analysis, we have observed in the present study that only echocardiographic score >8 and the presence of severe mitral regurgitation before mitral balloon valvuloplasty are independent factors predicting death in long term follow up In the literature, Dean et al 66 found age >70 years old, FC IV before the procedure and echocardiographic score >12 as factors predicting death using univariate analysis, in a 4-year-follow-up. Using multivariate analysis, the independent factors predicting death found were echocardiographic score, FC IV before the procedure, high echocardiographic score, increased systolic pulmonary blood pressure, and end diastolic left ventricle pressure after the procedure. Palacios et al 54 found as independent factor predicting death in the multivariate analysis, echocardiographic score, increased age of the patients and high functional class before the procedure.

In the multivariate analysis, independent factors predicting death in the long term follow up in this study were: history of surgical mitral commissurotomy, atrial fibrillation before the procedure, severe mitral regurgitation during the procedure, and procedure failure (mitral valve area ≤1.50 cm²). In the literature independent factors for events are: lower mitral valve area after the procedure20,37,40,45,59,67, atrial fibrillation20,22,23,51, history of surgical mitral commissurotomy24,45,46,53,54, presence of severe mitral regurgitation after the procedure20,24,27,34,53,54, increased functional class before the procedure20,22,24,48,54, increased echocardiographic score before the procedure23,24,26,37,40,48,54, increased age20,21,22,23,24,54, unfavourable mitral valve anatomy20,21,22,23,38,59, increased mean pulmonary blood pressure after the procedure21,24,40, increased transvalvular gradient after the procedure20,21,22,46,51, increased left atrium pressure after the procedure or enlarged left atrium36,46,59, male gender46, increased cardiac thoracic index21,45, presence of co-morbidities36, and increased final left ventricle pressure48.

The present study concluded that mitral balloon valvuloplasty is an efficient procedure. Survival and event free survival combined with death, new mitral balloon valvuloplasty and mitral surgery were high at the end of the follow-up period, and more than two third of the total group of patients were event free by the end of the study. In the patients with echocardiographic score ≤8 before the procedure compared with the score group > 8, survival and event free survival observed were significantly greater. Echocardiographic score also separates 3 groups with different survival curves (≤8, between 9 and 11 and ≥ 12), (fig. 2 and 3). Echocardiographic score higher than 8 and the presence of severe mitral regurgitation were risk factors for death in the long term follow-up. The history of surgical mitral commissurotomy, presence of atrial fibrillation before the procedure, mitral valve regurgitation during the procedure, atrial fibrillation before the procedure, severe mitral regurgitation during the procedure and mitral valve area lower than 1.5 cm² after the procedure, were risk factors for combined events in the end of the follow-up period of these patients.

References


